We are live on ! Find out more
KALV

KalVista Pharmaceuticals
KALV

Delisted

KALV was delisted on the 10th of June, 2026.

Back to rankings

139 hedge funds and large institutions have $616M invested in KalVista Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 30 funds opening new positions, 55 increasing their positions, 31 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,091% more call options, than puts

Call options by funds: $12.4M | Put options by funds: $1.04M

77% more repeat investments, than reductions

Existing positions increased: 55 | Existing positions reduced: 31

67% more first-time investments, than exits

New positions opened: 30 | Existing positions closed: 18

9% more funds holding

Funds holding: 128 → 139 (+11)

0.95% less ownership

Funds ownership: 110.46% → 109.51% (-0.95%)

4% less capital invested

Capital invested by funds: $640M → $616M (-$24.9M)

17% less funds holding in top 10

Funds holding in top 10: 6 → 5 (-1)

Holders
139
Holders Change
+11
Holders Change %
+8.59%
% of All Funds
1.83%
Holding in Top 10
5
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-16.67%
% of All Funds
0.07%
New
30
Increased
55
Reduced
31
Closed
18
Calls
$12.4M
Puts
$1.04M
Net Calls
+$11.4M
Net Calls Change
-$4.36M

Top Buyers

Rank Fund Capital Flow
1
Ameriprise
Ameriprise
Minnesota
+$11.1M
2
WP
Woodline Partners
California
+$3.71M
3
State Street
State Street
Massachusetts
+$3.13M
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$2.96M
5
PAM
Panagora Asset Management
Massachusetts
+$2.7M

Top Sellers

Rank Fund Capital Flow
1
GPP
Great Point Partners
Connecticut
-$8.45M
2
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
-$5.78M
3
SSA
Schonfeld Strategic Advisors
New York
-$5.34M
4
AI
Allostery Investments
Connecticut
-$5.11M
5
JP Morgan Chase
JP Morgan Chase
New York
-$4.64M
Name Holding Trade Value Shares
Change 		Change in
Stake
Daiwa Securities Group
126
Daiwa Securities Group
Japan
$2K – – –
LFG
127
Larson Financial Group
Missouri
$1.88K +$269 +22 +15%
CIBC Private Wealth Group
128
CIBC Private Wealth Group
Georgia
$1.81K – – –
RIL
129
Rothschild Investment LLC
Illinois
$1.58K +$428 +35 +33%
A
130
AlphaQuest
New York
$1.48K +$1.6K +131 New
TFA
131
Toth Financial Advisory
Virginia
$1.13K +$1.22K +100 New
SS
132
SBI Securities
Japan
$1.06K – – –
SCM
133
Sterling Capital Management
North Carolina
$1.03K +$611 +50 +122%
TWD
134
True Wealth Design
Ohio
$656 -$1.05K -86 -60%
PWA
135
Physician Wealth Advisors
Utah
$577 +$624 +51 New
AF
136
Allworth Financial
California
$509 +$171 +14 +45%
IA
137
IFP Advisors
Florida
$498 -$49 -4 Closed
PFBT
138
Parkside Financial Bank & Trust
Missouri
$453 +$489 +40 New
EP
139
Essential Partners
California
$430 +$465 +38 New
PWM
140
Parkworth Wealth Management
California
$249 +$269 +22 New
JFG
141
Jefferies Financial Group
New York
– -$4.33M -375,000 Closed
Adage Capital Partners
142
Adage Capital Partners
Massachusetts
– -$3.19M -276,000 Closed
Walleye Capital
143
Walleye Capital
New York
– -$3.05M -249,161 Closed
NFGH
144
Nan Fung Group Holdings
Hong Kong
– -$1.78M -154,522 Closed
DP
145
Diadema Partners
New Jersey
– -$1.56M -135,509 Closed
PAP
146
Persistent Asset Partners
Hong Kong
– -$393K -34,098 Closed
HS
147
HighVista Strategies
Massachusetts
– -$384K -33,305 Closed
PP
148
PDT Partners
New York
– -$273K -23,654 Closed
CF
149
Corebridge Financial
Texas
– -$220K -19,094 Closed
IC
150
IEQ Capital
California
– -$126K -10,915 Closed
3 4 5
6
7

KALV Hedge Fund Activity: Q2 2025 in Review

139 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in KalVista Pharmaceuticals (KALV) for Q2 2025, worth a combined $616M — down 3.9% from $640M a quarter earlier.

Buyers outnumbered sellers: 30 funds opened new KALV positions and 18 closed out — a net gain of 12 holders — while 55 added to existing stakes and 31 trimmed.

The largest buyer was Ameriprise, adding an estimated $11.1M. The largest seller was Great Point Partners, cutting an estimated $8.45M.

  • 139 institutional investors held KalVista Pharmaceuticals (KALV) as of Q2 2025, up from 128 in Q1 2025.
  • Funds reported $616M of KalVista Pharmaceuticals stock for Q2 2025, down 3.9% quarter-over-quarter.
  • 30 funds opened new KalVista Pharmaceuticals positions in Q2 2025 and 18 closed out, a net change of +12 holders.
  • The largest KalVista Pharmaceuticals buyer in Q2 2025 was Ameriprise, an estimated $11.1M added.
  • The largest KalVista Pharmaceuticals seller in Q2 2025 was Great Point Partners, an estimated $8.45M sold.

Based on aggregated 13F filings for Q2 2025.